Ryan Cross the Science Boss (@RLCscienceboss) header
Ryan Cross the Science Boss (@RLCscienceboss) profile picture

Senior Science Correspondent for @Endpts covering biotech, drug discovery, gene editing, RNA, and more. Formerly at Boston Globe and C&EN. Signal: RyanCross.25

Joined February 2015
Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)Photo by Ryan Cross the Science Boss (@RLCscienceboss)
The Science Boss is back! It's my first day at @endpts, a @FinancialTimes co. I'll be writing news, analysis, and features as the Senior Science Correspondent for Endpoints, with a focus on the science, reseach, and tech of biomed, biotech, and pharma. [email protected]
12
8
111
13,238
Lilly’s dopamine drug mevidalen fails Phase 2 study in Alzheimer’s, according to data at #CTAD26. The company hasn't said much about the pill, but it was one of its efforts to branch out beyond amyloid antibodies. My story for @endpts has the details: endpoints.news/ctad26-lillys…
2
434
Biogen’s tau-silencing drug diranersen slows Alzheimer’s by 38% after nearly two years, up from 26% slowing after 18 months, according to data at #CTAD26. But lots of caveats, including a small group and imperfect placebo comparison. Details in @endpts - endpoints.news/ctad26-biogen…
6
596
Cognito plans FDA submission of light and sound therapy for Alzheimer’s despite missing its primary endpoint in both the overall population and mild disease subgroup. Data of pivotal study presented at #CTAD26. My story for @endpts has the details: endpoints.news/ctad26-cognit…
1
366
For nearly a decade, the German biotech Priavoid has been working on a pill to break up small clumps of amyloid proteins. In a 300-person study presented at #CTAD26 this morning, the drug failed to slow Alzheimer's disease. More details in @endpts: endpoints.news/priavoids-amy…
229
A shocking twist in the sickle cell saga. Nearly 3 years after the FDA approved two one-and-done gene therapies for the disease, a new startup has raised $173M for siRNA drug, dosed chronically, that targets the same gene as the CRISPR therapy. @endpts: endpoints.news/marrow-raises…
2
2
17
7,522
AriBio’s repurposed erectile dysfunction drug for Alzheimer’s disease yields tepid results: no significant difference from placebo in overall study, but 31% slowing of cognitive decline in people who weren't on two other common Alzheimer's drugs. @endpts endpoints.news/aribios-repur…
2
3
698
"If we’re not, in the US, providing an outlet for our scientific discovery to move toward patient benefit, others will step into that void, and that’s what we’re seeing." More on cancer's translation problem in my Q&A with Parker Institute's Karen Knudsen endpoints.news/parker-instit…
1
224
Seawolf launches with $100M to make non-viral gene therapies for obesity, muscle loss and osteoporosis. The startup told me the key to delivering DNA with LNPs was a protein that blocks the cell's natural sequestration of foreign DNA. More in @endpts endpoints.news/seawolf-launc…
1
1
9
5,730
Endpoints News is hiring a "Business of Science" reporter! We're looking for someone with experience covering the biotech industry with business savvy and an ability to make sense of important advances in science and medicine. @endpts linkedin.com/jobs/view/44899…
2
6
749
Ferring Pharma, one of the biggest sellers of fertility drugs used in IVF, plans to acquire the ovary-in-a-dish startup Gameto for up to $1.38B. Gameto has made iPSC-derived ovarian support cells that help mature human eggs in the lab. Read more @endpts: endpoints.news/ferring-to-ac…
9
4
31
8,048
China biotech RiboX reveals first data of a circular RNA therapy in people, with benefits seemingly lasting six months. “That seems pretty crazy, but it’s possible, I guess,” an RNA biologist in Boston told me. My story for @endpts has the details: endpoints.news/china-biotech…
1
3
936
Arrowhead’s brain-targeting siRNA, administered as a subcutaneous injection, lowers the Alzheimer’s protein tau in early study. Lots of work ahead here, but good news for delivery tech designed to cross the blood-brain barrier. My story for @endpts: - endpoints.news/arrowheads-br…
286